Skip to content

Current ratio at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
2.5×+1.1×
Viatris logo
ViatrisVTRS
1.6×-0.1×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
ALN
Alnylam PharmaceuticalsALNY
3.1×+0.1×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
5.5×-0.4×
Amgen logo
AmgenAMGN
1.3×+0.1×

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×

Where this comes from

Calculated from ANI Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's current ratio?
ANI Pharmaceuticals (ANIP) reported current ratio of 3.1× in Q1 2026.
How has ANI Pharmaceuticals's current ratio changed year-over-year?
ANI Pharmaceuticals's current ratio increased by 17.4% year-over-year, from 2.7× to 3.1×.
What is the long-term trend for ANI Pharmaceuticals's current ratio?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's current ratio has grown at a 4.5% compound annual growth rate (CAGR), from 2.2× to 2.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.